EN
抗体药类似物
Research Grade Lebrikizumab
All
TD-HW632026_1.jpg
  • CatalogTD-HW632026
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsMILR1444A, PRO301444, CAS: 953400-68-5
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Lebrikizumab


Catalog No. TD-HW632026
Species reactivity Human
Applications Research Grade Biosimilar
Host species Humanized
Isotype IgG4-kappa
Expression system Mammalian Cells
Species Human
Clonality Monoclonal
Target IL13, NC30, Interleukin-13, IL-13
Endotoxin level Please contact with the lab for this information.
Purity >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession P35225
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate Names MILR1444A, PRO301444, CAS: 953400-68-5
Background Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases.
Note For research use only. Not suitable for clinical or therapeutic use.

 

TD-HW632026_1.jpg
Bioactivity
 
Detects Human IL13 in indirect ELISAs.